Allergan to buy Tobira in push for NASH treatments

Sept 20 (Reuters) - Allergan Plc said it would buy

Tobira Therapeutics Inc in a deal worth up to $1.7

billion, to gain access to its experimental therapies for a

fatty liver disease called NASH.

Read more